NASDAQ:DEPO Depomed (DEPO) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free DEPO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.09▼$7.4250-Day Range N/A52-Week Range$4.31▼$9.48Volume940,193 shsAverage Volume1.30 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Depomed alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Depomed Stock (NASDAQ:DEPO)Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. DEPO Stock News HeadlinesOctober 30, 2023 | finance.yahoo.comVulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030August 29, 2023 | thestreet.comHorizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion BidApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.August 13, 2023 | thestreet.comWhy DepoMed (DEPO) Stock Is Gaining TodayJuly 31, 2023 | finance.yahoo.comSurge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028July 8, 2023 | thestreet.comOpioid Litigants Get Boost From Senate ReportMay 17, 2023 | marketwatch.comChronic Fatigue Syndrome Therapeutics Drug Market Till 2030May 12, 2023 | marketwatch.comPain Management Market Size, Outlook, Trends, Share by 2030April 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.May 11, 2023 | marketwatch.comGlobal Neuropathy Pain Treatment Market [2023] | Industry Set to Expand with Strong 3.4% CAGR and Reach USD 10560 Million by 2030May 10, 2023 | msn.comHow Turkey's opposition is taking the taboo out of the headscarf debateApril 29, 2023 | marketwatch.comGlobal Gabapentin Market by Size, Scope 2023: with Development Status 2031April 23, 2023 | marketwatch.com2023-2030 Chronic Pain Management Drugs Market Size with Manufactures and Upcoming OpportunitiesApril 17, 2023 | thestreet.comDepomed, Insys Shares Down After FDA Decision on Endo's Opana ERApril 15, 2023 | marketwatch.comPeripheral Neuritis Treatment research report leads towards the developing of this industry with an estimated CAGR 11.1% during 2023-2030April 13, 2023 | marketwatch.comNeuropathy Pain Treatment Market Growth Prediction and Segment Insight 2023-2107April 5, 2023 | marketwatch.comNeuropathy Pain Treatment Market 2023 Size and Forecast to 2031March 30, 2023 | marketwatch.comVulvodynia Treatment Market: Overview of the Regional Outlook 2023-2030March 14, 2023 | marketwatch.comPain Management Market Size, Growth | Soaring Demand | 2023 - 2029March 13, 2023 | marketwatch.comPain Relief Medications Market Research Report 2023-2028 with Top Countries DataFebruary 21, 2023 | marketwatch.comDiabetic Neuropathy Treatment Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028February 3, 2023 | marketwatch.comControlled Release Drug Delivery Market 2023 Expected to Reach Significant Rate by 2029January 29, 2023 | marketwatch.comNeuropathy Pain Treatment Market Growth, Size, Share, Opportunities, Industry Analysis and Forecast 2023 To 2028January 23, 2023 | thestreet.comCFO Says Depomed to Buy or Be SoldJanuary 3, 2023 | marketwatch.comNeuropathic Pain Management Market Size, Share and Forecast 2028 with Top Countries DataOctober 15, 2022 | newsweek.comJ.D. Vance Cancels Fundraiser Planned by Doctor Mentioned in Opioid Lawsuit - NewsweekOctober 12, 2022 | marketwatch.comPain Management Drugs Market is Growing Worldwide | 133 Report PagesSee More Headlines Receive DEPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2018Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DEPO CUSIP24990810 CIK1005201 Webwww.depomedinc.com Phone(224) 419-7106FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDaniel A. PeisertPresident, Chief Executive Officer & DirectorPaul SchwichtenbergChief Financial Officer & Senior Vice PresidentAjay PatelChief Accounting Officer & Senior Vice PresidentMegan C. TimminsSecretary, Senior Vice President & General CounselMax NemmersHead-Investor Relations & AdministrationKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors DEPO Stock Analysis - Frequently Asked Questions How were Depomed's earnings last quarter? Depomed, Inc. (NASDAQ:DEPO) posted its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company earned $63.27 million during the quarter, compared to analyst estimates of $63.72 million. The firm's revenue for the quarter was down 37.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 earnings per share. What other stocks do shareholders of Depomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Vertex Pharmaceuticals (VRTX), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP), Bausch Health Companies (BHC), Gilead Sciences (GILD), Allergan (AGN) and Bristol-Myers Squibb (BMY). This page (NASDAQ:DEPO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Depomed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
